الفهرس Only 14 pages are availabe for public view
 |  | from | 211 |  |  |
| | | from | 211 | | |
Abstract
Breast cancer is the most frequently diagnosed cancer in women and the second most frequent cause of death.
This study aimed to assess whether the concomitant or the sequential
addition of tamoxifen to chemotherapy provides improved clinical benefit
in the adjuvant treatment in operable breast cancer patients.
Patients and Methods
This is a prospective study carried at a Clinical Oncology Department Zagazig University on 80 patients with stage I, II, TIT, ER& PR + VE operable breast cancer for adjuvant treatment after surgery.
Pretreatment evaluation included complete history,Physical examination, complete blood count, chemistry,chest X-ray, pelvi- abdominal ultrasonography, mammography on the contralateral breast, bone scan, cardiac evaluation, tumor marker assay (CA 15-3), CT brain
when indicated.
The pationts randomized into 2 therapeutic groups. Group A ”Sequential arm” where 6 cycles Epirubcin + cyclophosphamide are given
followed by hormonal therapy ”Tarnoxifen” which Started 21 days after the sixth cycle.
Group B ”Concomitant arm” where 6 cycles EC were given by the
same dose concomitantly with hormonal therapy ”Tamoxifen” which
started from the beginning of the first cycle. Radiotherapy will be given in both groups according to the
indication.